2 Outstanding Dividend Stocks to Buy and Hold for 10 Years

Johnson & Johnson's shares are up 28% this year versus a 10% S&P 500 gain, supported by Q2 sales growth of 6.6% to $25.3B and adjusted EPS growth of 4.7% to $2.90. Its 64-year dividend-increase streak, new product approvals, diversified pharmaceuticals and medtech portfolio, and progress toward resolving talc litigation support its long-term income case. Merck grew Q2 revenue 5% to $16.6B, with Winrevair sales up 75% to $588M and Capvaxive revenue up 42% to $184M, though it faces Keytruda competition and a 2028 patent-expiry risk; management's subcutaneous Keytruda Qlex strategy and pipeline are positioned to mitigate the patent cliff.

Analysis

JNJ’s relative outperformance likely leaves less room for further multiple expansion; the investable question is whether medtech can become a durable second growth engine rather than merely offset pharmaceutical LOEs. Ottava creates an eventual competitive challenge to ISRG, but commercialization, hospital capital-budget cycles, and surgeon adoption mean any revenue contribution is a 2027-29 issue, not a near-term earnings catalyst. A final talc resolution would reduce the equity risk premium and support incremental buybacks, but only if cash funding and residual claimant exposure are materially below current reserve assumptions.

MRK remains a patent-cliff execution story, not a dividend-growth story. The subcutaneous Keytruda strategy can preserve administration convenience and some channel stickiness, but it does not eliminate payer incentive to migrate to biosimilars after 2028; net price, formulary positioning, and conversion rates matter more than approval status. Winrevair is the key nearer-term offset, while MRNA’s oncology program is a longer-duration option whose value depends on confirmatory durability, regulatory path, manufacturing economics, and MRK’s share of profit pool.

Consensus may be too sanguine on both companies’ ability to replace mature-franchise economics dollar-for-dollar. JNJ has lower single-asset risk and litigation optionality, whereas MRK offers greater upside if post-Keytruda assets scale but has materially higher 2028-30 estimate risk; that asymmetry favors a relative trade rather than a broad long-biopharma expression.

Key Decisions for Investors

• No immediate standalone JNJ chase after its strong relative move; establish an alert to add only following a 8-10% pullback or a talc settlement that quantifies total cash cost and eliminates meaningful residual litigation. Thesis fails if settlement funding materially impairs buyback capacity or pharma/medtech organic growth decelerates below mid-single digits for two consecutive quarters.
• Initiate a 6-12 month long JNJ / short MRK beta-neutral pair in modest size. The trade captures JNJ’s diversified cash-flow and litigation de-risking versus MRK’s increasing sensitivity to post-2028 Keytruda replacement assumptions; reassess if Winrevair annualized sales trajectory and new-product guidance demonstrate enough scale to close the expected Keytruda gap.
• Treat MRNA as a watch-list catalyst rather than a recommendation: verify the melanoma study’s endpoint, durability, safety, and commercial profit-sharing terms before underwriting value. Positive regulatory-quality data could improve MRK pipeline optionality over 12-24 months, but a weak durability update would remove a prominent post-Keytruda narrative support.
• Monitor ISRG and robotic-surgery capital spending as a second-order read-through on JNJ’s surgical automation opportunity. Strength in ISRG procedure growth validates category demand but also raises the execution bar; JNJ should not receive material valuation credit for Ottava until hospital placements and utilization are disclosed.